HCV-positive status and hepatitis flares in patients with B-cell non-Hodgkin's lymphoma treated with rituximab-containing regimens

详细信息    查看全文

• 作者：Massimo Marignani^a ; ^{mmarignani@hotmail.com} ; Manuela Mangone^a ; M. Christina Cox^b ; Stefano Angeletti^a ; Barbara Veggia^b ; Antonella Ferrari^b ; Michela di Fonzo^a ; Paola Begini^a ; Elia Gigante^a ; Giacinto Laverde^b ; Antonietta Aloe-Spiriti^b ; Bruno Monarca^b ; Gianfranco Delle Fave^a
• 关键词：B-cell non-Hodgkin's lymphoma ; Chemotherapy ; Hepatitis C virus ; Rituximab
• 刊名：Digestive and Liver Disease
• 出版年：2011
• 出版时间：February 2011
• 年：2011
• 卷：43
• 期：2
• 页码：139-142
• 全文大小：131 K

文摘

Background

Rituximab has provided a revolutionary contribution to the treatment of B-cell non-Hodgkin's lymphomas (NHL). A high prevalence of hepatitis C virus (HCV) infection has been described in B-cell NHL patients. Cases of liver dysfunction in HCV-positive patients have been reported with rituximab-containing regimens.

Aim

to evaluate the liver-related effects of rituximab-containing regimens on HCV-positive CD20-positive B-cell NHL patients.

Patients and methods

Retrospective analysis of 104 consecutive patients. HCV status was determined, and development of hepatitis flares analysed.

Results

Nine patients (8.6 % ) were HCV-positive. No correlation was shown between viral load and alanine transaminase levels. Three of the 9 HCV-positive, and none of the 95 HCV-negative developed hepatitis flares (p < 0.001). At the 12-month follow-up hepatitis flare patients were alive and in remission for their haematological disease and no hepatitis flares, liver-related death had developed.

Conclusions

HCV-positive status may represent a risk factor for the development of hepatic flares in B-cell NHL patients receiving rituximab-containing regimens. Despite the increase in liver function tests, there were no major clinical events.